Boston Scientific price target raised to $115 from $110 at BofA

BofA raised the firm’s price target on Boston Scientific (BSX) to $115 from $110 and keeps a Buy rating on the shares. The firm notes the company grew organic revenues 19.5% in Q4 and the initial conservative guide for 2025 came in at 10%-12% organic growth. The Q1 guide was also strong at 14%-16%. This puts Boston Scientific as one of the fastest growing companies in MedTech, argues BofA. This best-in-class growth is starting to look even more durable than most had expected, the firm adds, noting that it sees upside to both the margin/EPS guide.